MicroRNA Profiling of the Inflammatory Response after Early and Late Asthmatic Reaction

Ruth P Duecker1, Oguzhan Alemdar1,2, Andreas Wimmers1,2

  • 1Department of Pediatrics, Division of Pneumology, Allergology, Infectious Diseases and Gastroenterology, University Hospital, Goethe University Frankfurt, 60590 Frankfurt am Main, Germany.

Insights

MicroRNAs (miRNAs) like miR-15a-5p, miR-15b-5p, and miR-374a-5p are downregulated in house dust mite-allergic asthma patients experiencing late asthmatic reactions. This finding may help predict late asthmatic reactions after allergen exposure.

Area of Science:

  • * Immunology and Respiratory Medicine
  • * Molecular Biology and Genetics

Background:

  • * Asthma patients with house dust mite (HDM) allergy often experience both early (EAR) and late asthmatic reactions (LAR), indicating more severe allergic inflammation.
  • * MicroRNAs (miRNAs) are crucial regulators in asthma pathogenesis, influencing inflammatory responses.

Purpose of the Study:

  • * To investigate the miRNA profile in mild asthma patients with HDM allergy following bronchial allergen provocation (BAP).
  • * To identify specific miRNAs associated with the development of late asthmatic reactions (LAR).

Main Methods:

  • * Seventeen patients with EAR/no LAR and 17 with EAR plus LAR were analyzed after BAP.
  • * Next-generation sequencing (NGS) was used for miRNA profiling.
  • * FEV1 (forced expiratory volume in 1 second) and eNO (exhaled nitric oxide) were measured.

Main Results:

  • * Patients with EAR plus LAR exhibited more significant allergic inflammation and a greater drop in FEV1 after 24 hours.
  • * NGS-miRNA analysis revealed significant downregulation of miR-15a-5p, miR-15b-5p, and miR-374a-5p in patients with EAR plus LAR.
  • * These downregulated miRNAs negatively correlated with eNO and maximum FEV1 decrease, and target genes involved in airway remodeling.

Conclusions:

  • * Specific miRNAs, including miR-15a-5p, miR-15b-5p, and miR-374a-5p, are downregulated in HDM-allergic asthmatics with LAR.
  • * These miRNAs and their targeted pathways are implicated in the inflammatory processes following allergen exposure.
  • * The identified miRNA profile may serve as a predictive biomarker for late asthmatic reactions.

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
403
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.6K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
298